When you are unpleasant, and a recurrence is recognized after an operation when it is judged that a curable operation (a surgical operation) is impossible for pancreatic cancer, treatment by the anticancer agent is performed.
Anticancer agent admitted in health insurance medical examination and treatment called gemushitabin seems to be used as a standard therapeutic drug now.
An effect to soften the symptoms such as the sharp pain by the pancreatic cancer seems to be able to be superior to gemushitabin in comparison with the used anticancer agent till now, but is said to be it to completely erase cancer if careless.
The insurance adaptation for the pancreatic cancer was accepted newly and got possible to use anticancer agent called TS-1 besides gemushitabin from August, 2006.
The curative effect in TS-1 which was anticancer agent of typing it internal use was still an evaluation stage, but, for patient expected chemotherapy with an outpatient and the oral agent from by what so far was added to anticancer agent of the insurance adaptation for the pancreatic cancer which there was few of the choice called the main force TS-1 an injection agent, choices of the treatment have increased.
